Drugs / TMP-301
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06648668 | Jan → May 2025 | substance-related disorder | Tempero Bio, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06025396 | Jan → Dec 2023 | substance-related disorder | Tempero Bio, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06648655 | Nov 2024 → Oct 2025 | alcohol-related disorders | Tempero Bio, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-01-05 | Nxera Pharma UK Limited | Regulatory Sosei Notes Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders nxera.life ↗ |
| 2023-01-05 | Nxera Pharma UK Limited | Regulatory Other nxera.life ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-03-25 | Nxera Pharma UK Limited | Nxera Pharma’s Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder nxera.life ↗ |
| 2023-01-05 | Nxera Pharma UK Limited | Sosei Notes Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders nxera.life ↗ |
| 2023-01-05 | Nxera Pharma UK Limited | Other nxera.life ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TMP-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06648655 ↗ |
| Route | Oral | “oral TMP-301, given concurrently with cocaine” NCT06648668 ↗ |